---
title: "BUZZ-PepGen, Dyne rise after Novartis' $12 bln deal to buy rival Avidity"
description: "Shares of PepGen rose 21% to $5.53, while Dyne Therapeutics surged 37.5% to $23.54 following Novartis' $12 billion acquisition of Avidity Biosciences. Both companies are developing treatments for rare"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/262933544.md"
published_at: "2025-10-27T15:24:34.000Z"
---

# BUZZ-PepGen, Dyne rise after Novartis' $12 bln deal to buy rival Avidity

> Shares of PepGen rose 21% to $5.53, while Dyne Therapeutics surged 37.5% to $23.54 following Novartis' $12 billion acquisition of Avidity Biosciences. Both companies are developing treatments for rare muscle disorders. RBC Capital Markets predicts Dyne will trade significantly higher due to its similar platform to Avidity, which has a market cap of $2.4 billion. Year-to-date, Dyne is up 1.8% and PepGen has increased 47.8%.

Shares of drug developer PepGen (PEPG.O) up 21% at $5.53, while Dyne Therapeutics (DYN.O) rise 37.5% at $23.54 Rival Avidity Biosciences (RNA.O) on Sunday agreed to be acquired by Swiss drugmaker Novartis (NOVN.S) for about $12 billion in cash to bolster its portfolio of treatments for rare muscle disorders

Pepgen and Dyne are also currently developing drugs to treat rare muscle disorders such as myotonic dystrophy type 1

“We anticipate DYN to trade materially higher tomorrow given similar platform, not materially behind RNA and $2.4b cap”- RBC Capital Markets

Including session moves, DYN up 1.8% and PEPG up 47.8% YTD

### Related Stocks

- [DYN.US - Dyne Therapeutics](https://longbridge.com/en/quote/DYN.US.md)
- [PEPG.US - PepGen](https://longbridge.com/en/quote/PEPG.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Avidity Biosciences, Inc. 的 $RNA 股份被 Candriam S.C.A. 收购 | Candriam S.C.A. 在第三季度增持了 Avidity Biosciences, Inc. (NASDAQ:RNA) 的股份，增幅为 10.2%，目前持有 487,917 股，市值为 2126 万美元。其他机构投资者也显著增加了他 | [Link](https://longbridge.com/en/news/275451342.md) |
| Circio 在筹集 7000 万挪威克朗资金后，广泛授予员工股票期权 | Circio Holding ASA 已推出员工股票期权计划，发行了 500 万个期权，筹集了 7000 万挪威克朗。此举旨在留住人才，同时将稀释限制在约 4%。期权定价为 1.18 挪威克朗，并设有多年的归属时间表，反映了管理层与股东保持 | [Link](https://longbridge.com/en/news/275972910.md) |
| 在全球疼痛市场中，新机制和新模式存在显著的机会 | 全球疼痛市场为创新提供了重大机会，特别是在开发非成瘾性替代阿片类药物方面。目前，全球批准的疼痛药物中有 98% 是仿制药，治疗选择缺乏多样性。Vertex Pharmaceuticals 的 Journavx 最近获得批准，标志着一个突破， | [Link](https://longbridge.com/en/news/275921122.md) |
| 威斯康星大学麦迪逊分校要求学生报告麻疹疫苗接种情况 | 威斯康星大学麦迪逊分校已要求学生披露其麻疹、腮腺炎和风疹等疾病的疫苗接种状态，此举是在校园内出现近期麻疹病例后实施的。该政策旨在增强公共健康意识，并为高风险学生提供更好的支持。此公告是在全国麻疹病例增加的背景下发布的，卫生官员呼吁进行疫苗接 | [Link](https://longbridge.com/en/news/275930065.md) |
| 05:30 ET 真实世界证据：后胫腱退化患者的疼痛和功能评分有所改善 | 来自大学足踝研究所和再生实验室的医生发表了一项经过同行评审的研究，探讨了脐带结缔组织同种异体移植物用于治疗对保守治疗无反应的后胫腱退化（PTTD）患者。研究显示，接受同种异体移植物的患者在疼痛和生活质量方面有显著改善，且未报告不良事件。这些 | [Link](https://longbridge.com/en/news/275740095.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.